INSM250117C82500
- 0.60
- 0.000.00%
Insmed Newsroom
Evercore Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $75
Insmed (INSM) Gets a Buy From Evercore ISI
Truist Financial Maintains Insmed(INSM.US) With Buy Rating
Wells Fargo Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $85
TD Cowen Maintains Insmed(INSM.US) With Buy Rating
TD Cowen Reaffirms Their Buy Rating on Insmed (INSM)
BofA Securities Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $90
Insmed Is Maintained at Overweight by JP Morgan
Insmed Analyst Ratings
J.P. Morgan Maintains Insmed(INSM.US) With Buy Rating, Raises Target Price to $83
BofA Securities Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $90
Truist Financial Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $105
Analysts' Opinions Are Mixed on These Healthcare Stocks: Haleon PLC Sponsored ADR (HLN), Insmed (INSM) and Galapagos (GLPG)
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $75 to $105
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $85 to $105
Insmed Price Target Maintained With a $90.00/Share by HC Wainwright & Co.
Insmed Analyst Ratings
Mizuho Securities Maintains Insmed(INSM.US) With Buy Rating
BofA Securities Maintains Insmed(INSM.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), GlaxoSmithKline (GSK) and Amylyx Pharmaceuticals Inc (AMLX)